2024
Lifetime prevalence, comorbidities, and Sociodemographic predictors of post-traumatic stress disorder (PTSD): the National Epidemiology of Iranian Children and adolescents Psychiatric disorders (IRCAP)
Hooshyari Z, Mohammadi M, Salmanian M, Ahmadi N, Khaleghi A, Garakani A. Lifetime prevalence, comorbidities, and Sociodemographic predictors of post-traumatic stress disorder (PTSD): the National Epidemiology of Iranian Children and adolescents Psychiatric disorders (IRCAP). European Child & Adolescent Psychiatry 2024, 1-14. PMID: 38656607, DOI: 10.1007/s00787-024-02441-7.Peer-Reviewed Original ResearchPrevalence of post-traumatic stress disorderPost-traumatic stress disorderTraumatic eventsAnxiety disordersStress disorderPsychiatric disordersSchool-Age Children-Present and Lifetime VersionKiddie Schedule for Affective DisordersSchedule for Affective DisordersLifetime prevalenceLifetime prevalence of post-traumatic stress disorderType of traumatic eventPredictors of post-traumatic stress disorderRates of PTSDSeparation anxiety disorderGeneralized anxiety disorderK-SADS-PLOppositional defiant disorderPrevalence of PTSDRates of comorbidityAdolescent psychiatric disordersLifetime prevalence ratesPrevalence rates of comorbiditiesDepressive disorderLifetime Version
2023
Psychedelics, With a Focus on Psilocybin: Issues for the Clinician
Garakani A, Alexander J, Sumner C, Pine J, Gross L, Raison C, Aaronson S, Baron D. Psychedelics, With a Focus on Psilocybin: Issues for the Clinician. Journal Of Psychiatric Practice 2023, 29: 345-353. PMID: 37678363, DOI: 10.1097/pra.0000000000000729.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsDisparities in program enrollment and employment outcomes for veterans with psychiatric and co-occurring substance use disorders referred or enrolled for VHA vocational rehabilitation
Sprong M, Hollender H, Lee Y, Williams L, Sneed Z, Garakani A, Buono F. Disparities in program enrollment and employment outcomes for veterans with psychiatric and co-occurring substance use disorders referred or enrolled for VHA vocational rehabilitation. Frontiers In Psychiatry 2023, 14: 1200450. PMID: 37520235, PMCID: PMC10382058, DOI: 10.3389/fpsyt.2023.1200450.Peer-Reviewed Original ResearchActive alcohol use disorderSubstance use disordersUse disordersVeterans Health Administration medical centersCo-occurring substance use disordersVocational rehabilitationProgram enrollmentCo-occurring alcoholCo-occurring depressionDiagnosis of anxietyCo-occurring diagnosesAlcohol use disorderPost-traumatic stress disorderInstitutional review boardVeteran patientsMedical CenterPsychiatric diagnosisCurrent studyBipolar disorderRehabilitation servicesReview boardStress disorderEffective interventionsAnxiety diagnosesDiagnosis
2021
The prevalence of post-traumatic stress disorder related symptoms in Coronavirus outbreaks: A systematic-review and meta-analysis
Salehi M, Amanat M, Mohammadi M, Salmanian M, Rezaei N, Saghazadeh A, Garakani A. The prevalence of post-traumatic stress disorder related symptoms in Coronavirus outbreaks: A systematic-review and meta-analysis. Journal Of Affective Disorders 2021, 282: 527-538. PMID: 33433382, PMCID: PMC7831964, DOI: 10.1016/j.jad.2020.12.188.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsConceptsPTSD symptomsCase-control studyPost-traumatic stress disorder symptomsPost-traumatic stress disorderPrevalence of PTSDCoronavirus outbreakWeb of ScienceCohort studySubgroup analysisInfectious disease outbreaksSources of heterogeneityHealthcare workersPrevalence ratesGeneral populationEligibility criteriaMeta-AnalysisSymptomsCoronavirus infectionStress disorderPrevalenceMental careMental healthSystematic searchMERS outbreakPresent COVID-19 pandemic
2020
Pharmacotherapy of Anxiety Disorders: Current and Emerging Treatment Options
Garakani A, Murrough JW, Freire RC, Thom RP, Larkin K, Buono FD, Iosifescu DV. Pharmacotherapy of Anxiety Disorders: Current and Emerging Treatment Options. Frontiers In Psychiatry 2020, 11: 595584. PMID: 33424664, PMCID: PMC7786299, DOI: 10.3389/fpsyt.2020.595584.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsSerotonin-norepinephrine reuptake inhibitorsSelective serotonin reuptake inhibitorsPosttraumatic stress disorderAnxiety disordersGABAergic medicationsReuptake inhibitorsRandomized double-blind placebo-controlled trialDouble-blind placebo-controlled trialPanic disorderStress disorderSpecific phobiaBeta-adrenergic medicationsPlacebo-controlled trialCurrent pharmacological treatmentsNorepinephrine reuptake inhibitorsSerotonin reuptake inhibitorsCause of disabilityPrevalent psychiatric disordersNovel pharmacotherapeutic agentsBeta-adrenergic agentsSocial anxiety disorderMixed antidepressantsGlutamate modulatorsGlutamatergic agentsObsessive-compulsive disorder
2012
Mental Health Approaches to Child Victims of Acts of Terrorism
Saraiya A, Garakani A, Billick SB. Mental Health Approaches to Child Victims of Acts of Terrorism. Psychiatric Quarterly 2012, 84: 115-124. PMID: 22736303, DOI: 10.1007/s11126-012-9232-4.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus Statements
2006
Neurobiology of anxiety disorders and implications for treatment.
Garakani A, Mathew SJ, Charney DS. Neurobiology of anxiety disorders and implications for treatment. Annals Of Global Health 2006, 73: 941-9. PMID: 17195879.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsConceptsPost-traumatic stress disorderCognitive behavioral therapyFear conditioningUnconditioned stimulusAnxiety disordersPartial NMDA agonistFear inhibitionFear extinctionTraumatic memoriesFear circuitryFear responsesPavlovian conditioningBehavioral therapyStress disorderSpecific phobiaNew learningAmygdala pathwayD-cycloserineAnti-anxiety treatmentPanic disorderPreliminary evidenceStimuliMemoryN-methyl-D-aspartate antagonistsNeurobiology